No black box warning on record for Kanjinti

As of the latest FDA labeling reviewed, Kanjinti (TRASTUZUMAB-ANNS) does not carry a black box warning. Standard warnings and precautions still apply — see the full Kanjinti medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Exacerbation of Chemotherapy-Induced Neutropenia. ( 5.5 , 6.1 ) 5.1 Cardiomyopathy Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ] . Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction

No black box warning on record for Kanjinti

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Exacerbation of Chemotherapy-Induced Neutropenia. ( 5.5 , 6.1 ) 5.1 Cardiomyopathy Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ] . Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction

Kanjinti Black Box Warning

No black box warning on record for Kanjinti

Other warnings & precautions

Kanjinti Black Box Warning

No black box warning on record for Kanjinti

Other warnings & precautions